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ABSTRACT
The still largely obscure molecular events in the glioblastoma oncogenesis, 
a primary brain tumor characterized by an inevitably dismal prognosis, impel 
for investigation. The importance of Long noncoding RNAs as regulators of gene 
expression has recently become evident. Among them, H19 has a recognized 
oncogenic role in several types of human tumors and was shown to correlate to some 
oncogenic aspects of glioblastoma cells. Here we, hypothesyze that in glioblastoma 
H19 exerts its function through the interaction with the catalytic subunit of the PRC2 
complex, EZH2. By employing a factor analysis on a SAGE dataset of 12 glioblastoma 
samples, we show that H19 expression in glioblastoma tissues correlates with that 
of several genes involved in glioblastoma growth and progression. H19 knock-down 
reduces viability, migration and invasiveness of two distinct human glioblastoma 
cell lines. Most importantly, we provide a mechanistic perspective about the role of 
H19 in glioblastoma cells, by showing that its expression is inversely linked to that 
of NKD1, a negative regulator of Wnt pathway, suggesting that H19 might regulate 
NKD1 transcription via EZH2-induced H3K27 trimethylation of its promoter. Indeed, 
we showed that H19 binds EZH2 in glioblastoma cells, and that EZH2 binding to NKD1 
and other promoters is impaired by H19 silencing.
In this work we describe H19 as part of an epigenetic modulation program 
executed by EZH2, that results in the repression of Nkd1. We believe that our results 
can provide a new piece to the complex puzzle of H19 function in glioblastoma.
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INTRODUCTION
Long noncoding (lncRNAs) RNAs are noncoding 
RNA molecules longer than 200 nucleotides that exert 
several regulatory functions, at both transcriptional and 
post-transcriptional level [1]. The number of annotated 
lncRNAs is constantly increasing in almost all species, 
thanks to the development of measurement techniques 
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(essentially based on Next Generation Sequencing, 
NGS) that allow for the detection of even very scarcely 
expressed molecules (as is often the case with lncRNAs). 
The scientific interest in these molecules peaked at the 
beginning of the century with the discovery of their role 
as important regulators of a wide range of physiological 
and pathological states. Still, a few lncRNAs had been 
discovered previously, even though only a small share of 
their function had been elucidated. Among these “older” 
lncRNAs, H19 is a 2.3 kb “oncofetal” RNA, maternally 
expressed and paternally imprinted, whose gene is located 
at 11p15.5, close to the telomeric region of chromosome 
11, and is reciprocally imprinted and regulated with its 
neighboring gene IGF2 [2]. Its expression is high during 
the embryonic period, but becomes barely detectable at 
birth and all along adult life, with the significant exception 
of a notably increased expression in tumors. This 
observation, along with the results of a growing number of 
studies, indicates that H19 works as an oncogene in several 
types of human cancers [3]. In the context of tumor cells, 
it was shown to work as a chromatin modifier through the 
recruitment of EZH2 to the promoter of target genes [4], 
as a competing endogenous RNA, sponging let-7 [5, 6], 
and also as the precursor for miR-675, in turn involved in 
tumorigenesis [7–12]. In both its transcriptional and post-
transcriptional roles, its expression in cancer cells was 
shown to be related to tumor dissemination and EMT, and 
in some cases to drug resistance[13–15].
Glioblastoma multiforme (GBM) is the most frequent 
and deadliest among malignant brain tumors, with an 
incidence of more than 3–4 cases per 100,000 per year [16], 
and is inevitably characterized by a dismal, always lethal 
prognosis. This remains true in spite of recent advances in 
surgical techniques and radiotherapy, flanked by adjuvant 
chemotherapy, which result in a median overall survival 
time of 12–18 months from diagnosis [17, 18]. The first 
observations of H19 expression in glioblastoma cells 
are relatively recent (last five years) and all indicate an 
oncogenic role of H19 mediated by enhancing migration/
invasion, proliferation as well as stemness. The molecular 
mechanisms described so far for an oncogenic role of H19 
in GBM range from H19 processing to produce miR-675 
[8, 19] to a function as sponge for miR-29a, in turn boosting 
tumor angiogenesis [20]. Our recent serial analysis of gene 
expression (SAGE) profiling of glioblastoma tissues [21] 
showed that H19 is overexpressed in tumor samples from 
short-term survivors compared to healthy white matter, 
but notably also in the same samples when compared to 
tumor tissues from long-term survivors. In addition, H19 
expression clearly differentiates tumor samples from short-
term survivors from samples excised from the peritumoral 
areas of the same patients.
Given the cumulative evidence pointing to H19 as 
an oncogene in glioblastoma, in this work we aimed to 
unravel the molecular basis of this role, with a specific 
focus on its possible involvement in the epigenetic 
modulation of gene expression mediated by EZH2 binding 
and trimethylation of H3K27 at regulatory regions.
RESULTS
The expression of the lncRNA H19 characterizes 
glioblastoma tissues and cell lines and correlates 
with that of several genes involved in glioblastoma 
growth and progression
In order to corroborate our previous findings about 
high H19 expression in glioblastoma [21], we searched 
the cancer gene expression database Oncomine (www.
oncomine.org) for H19 expression in glioblastomas, 
and found that it is significantly overexpressed in GBM 
samples as compared to healthy brain control tissues. 
Figure 1A depicts H19 expression in three GBM datasets 
present in Oncomine. In all of them, H19 is in the top 
5% of overexpressed genes in GBM vs healthy controls 
and its fold change ranges from 2.4 (Liang dataset, p = 
8.80E-5) through 2.7 (Sun dataset, p = 8.35E-13) to 
3.2 (Murat dataset, p = 2.13E-11). We then employed a 
factor analysis approach to study H19 expression in our 
GBM sample cohort (12 glioblastoma tissues, described 
in ref.21); in this data reduction approach, a large set 
of correlated variables is mapped to a smaller set of 
uncorrelated linear combinations (factors) of the original 
variables along with the relative contributions (loadings) 
of each variable to each factor. This yields a small set 
of uncorrelated variables from a large set of variables 
(most of which are correlated to each other). Thus, when 
considering only genes with loadings >0.5, (loadings are 
expressed with values from 0 to 1, the higher this number, 
the more that gene contributes to that factor) we found that 
H19 expression is clearly associated with a single factor 
(loading = –0.85 on the second factor extracted, which 
explained 17% of total variance), which also collects other 
genes strongly involved in GBM development. These 
include LIF, induced by TGFβ in GBM initiating cells and 
supporting their self-renewal and migration ability [22], or 
other genes working in glucose metabolism, as hexokinase 
3 (HK3), or in detoxification of ROS, as glutathione 
peroxidase 3 (GPX3) [23]. These are all processes 
perturbed in GBM and in many cases necessary for its 
growth and spreading. All genes with loadings greater 
than 0.5 on the same factor as H19 are shown in Table 1. 
Complete factor analysis results (in terms of loadings) are 
shown in Supplementary Table 1.
Successively, with the aim of establishing an 
in vitro system where studying the role of H19 in GBM, we 
checked H19 expression levels in 5 human glioblastoma 
cell lines by comparing them with a healthy white matter 
sample. As shown in Figure 1B, the LN229 and A172 cell 
lines are those with the highest expression of H19. For 
this reason, we chose these two cell lines to perform our 
experiments of H19 knock down.
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The lncRNA H19 affects viability, migration and 
invasiveness of glioblastoma cells
In order to understand if H19 high expression levels 
contribute to the oncogenic properties of GBM cells, 
we depleted H19 by siRNAs (Figure 2A and 2B and 
Supplementary Figure 1A) and measured cell viability 
and in vitro ability to migrate and invade through an 
artificial ECM (transwell assays).We assayed three 
different siRNAs targeting H19, and demonstrated that 
all of them efficiently knocked down H19 in both A172 
and LN229 cells (Supplementary Figure 1B). Due to its 
high efficiency, we then chose siRNA3 (from now on 
named “siRNAH19”) for the following experiments. 
As shown in Figure 2C and Supplementary Figure 1C, 
H19 knock-down strongly reduced the viability of A172 
cells, while it had a more slight, though significant, 
effect on LN229 cells (Figure 2D). In both cases, the 
decrease in viability was evident at late time points. 
Conversely, H19 depletion reduced both migration 
and invasiveness more in LN229 (Figure 2E and 2F) 
than in A172 cells, where we observed only a trend 
(Figure 2E and 2F, and Supplementary Figure 1D). 
However, even with the differences we detected in our 
two cell lines, these results indicate that H19 plays a 
role in the growth and motility of GBM cells. As H19 is 
also the precursor of miR-675, we also measured miR-
675-5p expression in LN229 and A172 cells, before and 
after H19 silencing. However, in both cell lines we found 
undetectable levels of miR-675-5p expression (data not 
shown). This strongly suggests that our functional results 
in conditions of H19 depletion are not due to miR-675 
inhibition, but rather to the inhibition of specific functions 
played by H19 as a lncRNA.
H19 localizes at both the cytoplasmic and 
nuclear region of glioblastoma cells 
LncRNAs can play their roles of gene expression 
regulators in several ways, implying distinct subcellular 
Figure 1: The lncRNA H19 is overexpressed in glioblastoma tissues and cell lines compared to heathy white matter. 
(A) Box-plots of relative H19 expression in glioblastoma and normal brain samples in three distinct datasets from Oncomine database 
(https://www.oncomine.org/). For each group of samples, the number in brackets represents the number of subjects analyzed. The horizontal 
lines represent the median values and the bottom and the top of the boxes correspond to the 25th and 75th percentiles, respectively. A non-
parametric t test was performed to calculate p values as indicated in the text. (B) RT-qPCR analysis of relative H19 expression in five human 
glioblastoma cell lines. All data are expressed as compared to H19 expression levels measured in a healthy white matter sample, set as = 1.
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localizations. As for H19, both cytoplasmic and nuclear 
roles have been reported [24, 25]; thus, we sought to 
determine its location in our cells. By employing Stellaris 
RNA FISH technology [26] to reveal H19 molecules 
in LN229 cells, we detected their presence both in the 
cytoplasm and in the nucleus of control cells (Figure 3A). 
As a further confirmation, we also searched for H19 
in U87-MG cells, which did not show any signal, in 
agreement with our RT-qPCR data (Figure 3A).
H19 knock-down increases the expression of 
Nkd1, an inhibitor of the canonical Wnt pathway
Among the roles previously demonstrated for 
H19 as a modulator of cancer cells, one mechanism of 
action in the nuclear compartment involves the epigenetic 
modulation of the expression of Nkd1, an inhibitor of 
Wnt pathway. In bladder cancer, H19 was shown to direct 
EZH2 to the promoter region of Nkd1, thus inducing the 
trimethylation of H3K27 and the consequent repression of 
transcriptional activity [4]. As the Wnt pathway is strongly 
involved in glioblastoma [27], we hypothesized that 
H19 might play the same role in glioblastoma cells. We 
silenced H19 by transfecting siRNAs into both A172 and 
LN229 cells (Figure 3B), and we measured Nkd1 mRNA 
and protein expression. As shown in Figure 3, upon 
knock-down of H19 both cell lines showed an increase in 
Nkd1 expression, at the mRNA (Figure 3B) as well as at 
the protein (Figure 3C) level, suggesting that this lncRNA 
might affect Nkd1 expression in glioblastoma cells.
H19 binds to EZH2 in glioblastoma cells and 
modulates global H3K27 trimethylation
In order to test if H19 can bind to EZH2 in 
glioblastoma cells, we performed RNA immunoprecipitation 
(RIP) experiments in LN229 cells transfected with a vector 
encoding a myc-tagged EZH2, (or EGFP as control). 
This analysis showed a statistically significant enrichment 
of H19 compared to IgGs in the immune precipitated sample 
of EZH2 expressing only (Figure 4A–4B). The H19-EZH2 
interaction was also supported by a computational approach 
by using the catRAPID algorithm [28], which predicted a 
good level of protein-RNA interaction propensity (45%) 
(Supplementary Figure 2). 
EZH2 is the catalytic subunit of the PRC2 complex, 
which works by inducing the trimethylation of H3K27 
[29]. We thus analyzed the effects of H19 modulation on 
H3K27 trimethylation. We silenced H19 by siRNAs and 
measured H3K27 trimethylation levels by Western blot, 
showing that it was significantly inhibited in both LN229 
and A172 cells (Figure 4C), in agreement with our model 
where H19 is positively involved in H3K27 trimethylation. 
In support of this, H3K27me3 levels were increased in 
A172 cells stably transfected with a vector encoding H19 
(Figure 4D–4E). As a further confirmation that H19 plays 
its role per se, and not simply as the precursor of miR-
675, we transfected cells also with p-H19-mut, a vector 
encoding a mutated form of H19, where miR-675 sequence 
has been mutated and miR-675 is not produced at all 
(Figure 4D). Even this mutated form of H19, lacking miR-
675, was able to increase H3K27 trimethylation (Figure 
4E), indicating that miR-675 is not involved in this effect.
The lncRNA H19 modulates EZH2 binding 
to the promoter regions of established EZH2 
targets
We proceeded in our characterization of the role 
of H19 in glioblastoma cells by investigating if, by 
modulating H19, we would be able to affect EZH2 
binding to promoters of genes known to be epigenetically 
regulated by PRC2-mediated trimethylation of H3K27 
[30]. As shown in Figure 5A, ChIP assays performed in 
A172 cells knocked-down for H19 revealed that H19 
depletion corresponded to a decrease of EZH2 binding 
Table 1: Genes with loadings greater than 0.5 (in absolute value) on the same factor on which H19 was found to have 
a loading of –0.85
Gene Loadings
CDCP1 −0.952807
CA3 −0.870870
H19 −0.857627
SLN −0.843568
TGFBI −0.800498
LIF −0.769733
GPX3 −0.717141
SCNN1B −0.703187
OCIAD2 −0.693885
HK3 −0.620037
SHCBP1 −0.563494
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to the NKD1 and PPP2R2B promoters, as well as to the 
regulatory region of MYT1 (which was used as a positive 
control for EZH2 binding). Moreover, we also showed 
that H3K27 trimethylation was reduced in the NKD1 
promoter upon H19 depletion, while the promoter region 
of PPP2R2B was not affected in its H3K27 trimethylation 
levels (Figure 5B).
These results were further confirmed when we 
repeated the same assays in LN229 cells. Indeed, 
H3K27me3 was strongly reduced in the NKD1 promoter 
(Figure 5C). Differently from A172 cells, LN229 did 
not show a clear enrichment of H3K27me3 marks in the 
PPP2R2B promoter, and H19 knock-down did not change 
H3K27me3 levels in that region (Figure 5C). Accordingly, 
Figure 2:  The knock-down of H19 reduces the viability and the migration and invasion ability of human glioblastoma 
cells. (A–B) Time course of H19 knock-down in A172 (a) and LN229 (b) human glioblastoma cells. The graph shows the results of 
RT-qPCR analysis of H19 relative expression in cells transfected with either a non-targeting, negative control siRNA (NC1) or a siRNA 
specifically targeting H19. At all the time points, H19 expression in siRNA H19-transfected cells is shown as compared to that of NC1-
transfected cells, set as = 1. (C–D) Viability (MTS) assays performed on A172 (C) and LN229 (D) cells transfected with either a negative 
control (NC1) or a H19 targeting siRNA, as in (A–B). Results in a-d are shown as the mean ± S.D. and represent the average of three 
experiments performed independently. Data were analyzed by a two-tailed unpaired Student’s t-test. *P < 0.05 **P < 0.01. (E–F) Migration 
(E) and invasion (F) transwell assays were performed in A172 and LN229 cells where H19 expression was knocked-down by siRNAs as in 
(A–B). The graph shows the number of migrating and invading cells as compared to cells transfected with a non-targeting, negative control 
siRNA (NC1). Results are presented as mean ± S.D. with significant differences from controls (*) shown (p < 0.05). Two-tailed unpaired 
t-tests were used to determine significance between groups. The experiments were performed three times (biological replicates).
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Figure 3: H19 localizes at both nuclear and cytoplasmic regions in LN229 glioblastoma cells, and its knock-down 
increases the expression of Nkd1. (A) Images showing H19 (left) and GAPDH (right) RNA molecules in LN229 and U87MG 
glioblastoma cells. Nuclei were counterstained by DAPI. Scale bar = 10 μm. (B) RTqPCR analysis of NKD1 expression in A172 (left) or 
LN229 (right) cells transfected with anti-H19 siRNAs. The graph shows the results of RT-qPCR analysis of H19 relative expression in cells 
transfected with either a non-targeting, negative control siRNA (NC1) or a siRNA specifically targeting H19. At all the time points, H19 
and NKD1 expression in siRNA H19-transfected cells is shown as compared to that of NC1-transfected cells, set as = 1. Results are shown 
as the mean ± S.D. and represent the average of three experiments performed independently. Data were analyzed by a two-tailed unpaired 
Student’s t-test. *P < 0.05. (C) The same cells as in (B) were assayed for Nkd1 protein expression by Western blot. Representative Western 
blots are shown in the upper panels for both A172 (left) and LN229 (right) cell lines, and quantifications are shown in the lower panels, 
where Nkd1 levels are expressed as the ratio between the silenced samples and the negative control (NC1) at each time point. Beta-actin 
expression is shown as the loading control.
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Figure 4: H19 is coimmunoprecipitated with EZH2 and its modulation affects global H3K27 trimethylation in 
glioblastoma cells. (A) Cells were transfected with either the negative control vector pEGFP or pMyc-EZH2, a vector encoding a 
Myc-tagged form of EZH2. Western blot analysis was performed with an antibody against EZH2. The first two lanes (input) show the 
results of EZH2 WB on total extracts, revealing both endogenous and ectopic EZH2. The remaining lanes, labelled as “IP”, represent 
proteins immunoprecipitated with either negative control IgGs (third and fourth lanes) or an anti-Myc antibody (fifth and sixth lanes). 
(B) H19 measurement by RT-qPCR on RNA extracted from the IP samples as in (A). Values derived from three independent experiments 
are reported as means ± s.e.m. and expressed as the percentage of the Input (% Input). Statistically significant differences are reported (*P 
< 0.05). (C) Representative western blot analysis (top) and quantification (bottom) of total H3 and H3K27me3 levels in A172 (left) or 
LN229 (right) cells at 48 h after transfection with either a negative control oligonucleotide (NC1) or an anti-H19 siRNA. Total H3 levels 
are used as loading controls. (D) H19 (left panel) or miR-675-5p (right panel) expression in A172 cells transfected with either the empty 
vector pCDNA3, or the H19-expressing vector pH19, or the vector pH19mut, encoding for a full length H19 mutated in the miR-675 
region. In both panels, data are expressed as compared to pCDNA3-transfected cells, where H19 and miR-675-5p levels are set as = 1. (E) 
Representative western blot analysis (left) and quantification (right) of H3K27me3 and total H3 (loading control) in the same A172 cells as 
in D. Results in (C–E) are shown as the mean ± S.D. and represent the average of three experiments performed independently. Data were 
analyzed by a two-tailed unpaired Student’s t-test. *P < 0.05.
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Figure 5: EZH2 is recruited to its target genes by means of H19. (A) qPCR analysis of ChIP assays with an anti-EZH2 antibody 
(a-EZH2) and, as controls, normal rabbit IgG (IgG) on chromatin from A172 cells silenced for H19 (siRNA H19) or with a non targeting 
siRNA (NC1), as a negative control. Data show the recruitment of EZH2 on the promoters of NKD1 and PPP2R2B, as well as to the regulatory 
region of MYT1, used as a positive control for EZH2 binding, and its displacement upon H19 knock down. (B) qPCR analysis of ChIP assays 
with anti-H3K27me3 antibody (a-H3K27me3) and, as controls, normal rabbit IgG (IgG) on chromatin from A172 cells silenced for H19 
(siRNA H19) or with a non targeting siRNA (NC1), as a negative control. Data show the enrichment of H3K27 trimethylation on the promoter 
region of NKD1 and its decrease after H19 knockdown. The promoter region of PPP2RB was assayed too, but no H3K27me3 enrichment was 
found in any condition. The enrichment of H3K27me3 on the regulatory region of MYOD1 is shown as a positive control of the ChIP. (C) 
qPCR analysis of ChIP assays with anti-H3K27me3 antibody (a-H3K27me3) and, as controls, normal rabbit IgG (IgG) on chromatin from 
LN229 cells silenced for H19 (siRNA H19) or with a non targeting siRNA (NC1), as a negative control. The promoter regions of NKD1 and 
PPP2R2B were assayed, and the enrichment of H3K27me3 on the regulatory region of MYOD1 is shown as a positive control of the ChIP. 
(D) qPCR analysis of ChIP assays with an anti-EZH2 antibody (a-EZH2) and, as controls, normal rabbit IgG (IgG) on chromatin from LN229 
cells silenced for H19 (siRNA H19) or with a non targeting siRNA (NC1), as a negative control. As in (A), the promoter regions of NKD1, 
PPP2R2B, and MYT1 were assayed. In all ChIP results, values derived from three independent experiments are reported as means ± S.D. and 
expressed as the percentage of the Input chromatin (% Input). Statistically significant differences are reported (*P < 0.05).
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EZH2 binding to NKD1 and MYT1 promoters was 
reduced by H19 silencing, while it was only slightly 
affected in the PPP2R2B promoter (Figure 5D). 
These results suggest that H19, by binding to EZH2, 
participates to EZH2 positioning on NKD1 and possibly 
other promoters, thus maintaining the trimethylated state 
of H3K27 and the repressed state of the related genes. 
DISCUSSION
The role of H19 as an oncogenic lncRNA is now 
clearly recognized, and several different modes through 
which it can promote tumorigenicity in different types of 
tumors have been demonstrated. The working mechanisms 
of H19 in cancer can be either epigenetic or post-
transcriptional, the former involving the interaction with 
one or more epigenetic protein modulators, while in the 
latter H19 sponges specific miRNAs, with a consequent 
specific target de-repression [3]. In glioblastoma, H19 
was first shown to act through its processing into miR-
675, in turn repressing Cadherin 13 [8]. An important 
function was shown for H19 in hypoxia-mediated 
angiogenesis, again via the production of miR-675, which 
induces HIF1α nuclear translocation and the consequent 
angiogenic cascade [12]. Moreover, under hypoxia, HIFα 
induces H19, which works as a molecular sponge for miR-
181d, relieving inhibition of β-catenin expression, and 
promoting oncogenic effects [31].
In this paper, we take a further step in the 
understanding of the oncogenic role of H19 in 
glioblastoma. We show that H19, endogenously expressed 
in glioblastoma cells, positively influences their growth 
and ability to migrate and invade. Given that miR-675 is 
almost undetectable in both A172 and LN229 cell lines, it 
is unlikely that these functional effects are due to miR-675 
expression. We hypothesize that the difference between our 
results and those described by other Authors [8, 19, 32] 
may be explained by the different cell lines used, as well as 
the respective miR-675 expression. Indeed, in the U87 cell 
line (widely employed in previous papers), we only found 
very low levels of H19 expression, possibly because in 
those cells H19 is mostly processed as miR-675 precursor. 
In agreement with our hypothesis, we also provide 
evidence of a nuclear role for H19 in LN229 cells, where it 
is highly expressed: for the first time, we were able to show 
H19 presence in the nuclear compartment - a finding that 
corroborates our hypothesis about its role as an epigenetic 
modulator. We demonstrated that endogenous H19 binds 
to EZH2, and that its depletion is sufficient to induce a 
general decrease of H3K27 trimethylation that, again, 
appears to be independent from miR-675 expression. More 
specifically, we demonstrated that the depletion of H19 in 
glioblastoma cells is translated into a specific reduction 
of EZH2 binding and H3K27 trimethylation at the NKD1 
promoter, with a consequent increase of Nkd1 levels. This 
protein, acting as a cell autonomous inhibitor of the Wnt 
pathway [33, 34], is involved in the modulation of cancer 
cell proliferation and migration/invasiveness in several 
types of solid tumors [30, 35, 36], where its expression is 
generally reduced compared to healthy tissues. Of note, 
the promoter region of NKD1 and those of other genes 
encoding for Wnt inhibitors are frequently hypermethylated 
in glioblastoma [37], where their expression is 
consequently very low. Even more directly related to our 
findings is the observation by Lin B. and colleagues [38] 
who, by studying H3K4me3 and H3K27me3 profiles in 8 
glioblastoma stem cell lines, found that NKD1 promoter 
contains H3K27me3 marks in 5/8 GBM stem cell lines. 
This supports and strengthens the results we obtained in 
established cell lines. We found a further confirmation that 
H3K27 trimethylation is a common feature contributing 
to the repressed state of NKD1 not only in cell lines 
but also in glioblastoma tissues, by data mining in The 
Canadian Epigenetics, Epigenomics, Environment and 
Health Research Consortium (CEEHRC). Therein, where 
H3K27me3 ChIP-seq data from 5 glioma patients’ tissues 
are deposited, we found that the regulatory region of 
NKD1 indeed contains peaks of H3K27 trimethylation. 
The peaks overlap with EZH2 binding sites, and one of 
them encompasses the region we have used for our ChIP 
studies on NKD1 regulatory region in the present work 
(Supplementary Figure 4). All this data, together with 
the recognized role of the Wnt pathway in glioblastoma 
[39], suggests a possible importance of NKD1 repression 
in glioblastoma oncogenesis. In our recent work, where 
we compared gene expression in glioblastoma tissues to 
peritumoral regions of the same patients, we observed 
that, while H19 was clearly overexpressed in tumors, the 
opposite was true for NKD1 (Log2FC peri vs tumor = 1.22, 
p = 0.0086) [21]. We now show for the first time that H19 
can regulate NKD1 expression in glioblastoma cells, and 
we suggest that NKD1 inhibition may be one of the ways 
through which H19 participates to glioblastoma growth.
Together with NKD1 modulation, we also report 
for the first time that H19 depletion in A172 glioblastoma 
cells results in a robust reduction of EZH2 binding to the 
promoter of MYT1, encoding for Myelin Transcription 
factor 1. Interestingly, MYT1 is a transcription factor 
involved in neuronal differentiation, that acts as a repressor 
of the neural progenitor transcriptional program [40], 
which is largely shared with that working in glioblastoma 
initiating cells. However, MYT1 expression remained 
undetectable in both A172 and LN229 cells even after 
H19 depletion (data not shown). As MYT1 transcription 
was shown to be induced by Ascl1, a transcription factor 
whose expression varies significantly between molecular 
subtypes of glioblastoma [41], we might speculate that 
this or other positive signals needed for MYT1 induction 
may be missing in our cell models, where thus H19 
depletion and the consequent reduction of EZH2 binding 
to MYT1 promoter would not be sufficient to switch its 
transcription on. 
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Our results point to a role for H19 as a component 
of an epigenetic regulatory complex in glioblastoma 
cells. H19 would cooperate with EZH2 in its repressive 
function on specific promoters, either driving or 
maintaining the PRC2 complex on targets. The 
interaction of H19 with the EZH2-centered regulation 
has been previously demonstrated in bladder carcinoma, 
where a mechanism analogous to the one hypothesized in 
this paper was proposed [4], and in ERα-positive breast 
cancer, contributing to chemoresistance [42]. Much 
more generally, H19 was shown to induce an increase 
of EZH2 levels in nasopharyngeal carcinoma cells, by 
working as a “sponge” for miR-630, thus sequestering 
it from its target, EZH2 mRNA [43]. We propose that 
H19 might contribute in more than one way to the EZH2-
mediated repression of key anti-tumor genes. Depending 
on the cell- and tumor specific context, either the nuclear 
function acting on specific promoters or the cytoplasmic, 
“sponge” role may prevail, with the two mechanisms very 
likely coexisting. Indeed, in the glioblastoma cell lines 
we have tested, we did not find evidence of a possible 
general effect of H19 depletion on EZH2 protein levels 
(Supplementary Figure 3A–3B). Moreover, in both cell 
lines the levels of miR-630 were close to undetectable 
(data not shown), thus not supporting the “sponge” 
role for H19 in these cells. In conclusion, in this work 
we describe H19 as part of an epigenetic modulation 
mechanism centered on EZH2, leading to the repression 
of NKD1, a gene involved in the negative regulation of 
the Wnt pathway. The here provided evidence unveils a 
new perspective on the role of this oncogenic lncRNA in 
glioblastoma.
MATERIALS AND METHODS
Cell lines, treatments and transfection
A172, LN229, U87MG, LN18 and T98G cell lines 
(ATCC, Rockville, MD, USA) were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal 
bovine serum (Aurogene) in a humidified atmosphere 
containing 5% CO2 at 37° C. Transfections were performed 
by Lipofectamine 3000 reagent (Invitrogen) using plasmid 
DNA or DsiRNA H19 (HSC.RNAI.NR_002196.12, which 
consists of 3 predesigned DsiRNAs for the same target, 
H19, a negative control, NC1, and positive controls for 
transfection, TYE, all from Integrated DNA Technologies, 
IDT) in Opti-MEM I (Invitrogen), as recommended by the 
manufacturer. 
Plasmids used: pcDNA3.1 empty vector (Clontech); 
pEGFP-C1 empty vector (Clontech); pCMV-Script H19 
(BamH1/EcoRI) kindly provided by Dr. Imad Matouk, 
the Hebrew University of Jerusalem, Israel; pCMV-Script 
H19 mut (BamH1/EcoRI) was generated by mutating the 
miR-675 sequence within H19 (3 nucleotides in the seed 
sequence of the miR and 3 nucleotides outside the seed). 
The primers used for mutagenesis were the following: 
For: 5′ tgtacaggcgaggtccgacagtggacttgg 3′
Rev: 5′ tgtcggacctcgcctgtacagaccctgggc 3′
p-Myc-EZH2 vector was kindly provided by Dr.ssa 
Daniela Palacios, Fondazione Santa Lucia IRCCS, Roma. 
The generation of stably transfected A172 cell lines 
was obtained by growing cells in medium containing the 
selective agent, G418, 1 mg/ml for three weeks.
RNA isolation, reverse transcription and 
Quantitative Real Time Polymerase Chain 
Reaction (RT-qPCR) 
Total cellular RNA was harvested with TRIzol 
LS Reagent® (Life Technologies), treated with DNase 
(Biolabs) for 40 min at 37° C, and reverse transcribed with 
M-MLV Reverse Transcriptase (Invitrogen), according to 
the manufacturer’s protocols. RT-qPCR was performed on 
the Applied Biosystems StepOne plus PCR System with 
PowerUp™ SYBR Green Master Mix (Life Technologies). 
The relative amount of each substrate was calculated by 
the 2–ΔΔCT method.
NKD1 and mir-675 expressions were measured by 
qRT-PCRs conducted on a StepOnePlus Real-Time PCR 
System (Applied Biosystems-Life Technologies) using 
TaqMan Universal PCR Master Mix and the specific TaqMan® 
Assays (probe and primer sets) (Applied Biosystems-Life 
Technologies). The small endogenous nuclear RNA U6 
(RNU6B) and TBP were used as controls for normalization. 
TBP, ID Hs99999910_m1; NKD1, Hs00263894_m1; 
RNU6B, ID 001093; hsa-miR-675-5p, 121124_mat.
The primers used in RT–qPCR analysis with SYBR 
Green Master Mix are listed in Table 2.
RNA immunoprecipitation (RIP)
RIP was performed starting from 1 mg of cleared 
lysate. Cell lysates were precleared with 20 µl of 
Dynabeads Magnetic (Invitrogen) and then were incubated 
with 3 µg of antibody in PBS Tween 0.02% for 2 h at 4° C 
in rotation. Furthermore, 30 µl of Dynabeads Magnetic 
were added to the protein extract and incubated 1 h at 
4° C in rotation. Protein-RNA complexes bound to beads 
were washed three times in NP-40 buffer (150 mM 
NaCl, 50 mMTris-HCl pH 8, 0.5% NP40, 10% glycerol, 
protease inhibitor cocktail and RNase inhibitor). The 
immunoprecipitates were divided in two parts for 
protein and RNA recovery. Proteins were eluted from 
beads by Laemmli sample buffer at 75° C 10 minutes. 
Co-precipitated RNA was treated 20 minutes at 37° C 
with proteinase K and recovered by phenol-chloroform 
extraction and ethanol precipitation and subjected to 
RT-PCR analysis. Primary antibodies for IP were mouse 
monoclonal anti-Myc (sc-40 Santa Cruz) or mouse IgG 
(Invitrogen).
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Western blot analysis
For Western blot analysis, total protein extract was 
isolated from A172 and LN229 cells by lysis in NP-40 
Buffer containing protease and phosphatase inhibitors 
(complete EDTA-free; Roche Applied Science), and protein 
concentrations were determined by Bradford method. 
Equivalent amounts of protein extract were separated by 
electrophoresis on 10% or 12% SDS-PAGE gels and blotted 
onto nitrocellulose. The membranes were blocked with 5% 
non-fat dry milk and 0.1% Tween-20 in Phosphate-buffered 
saline and then incubated with antibodies followed by 
appropriate horseradish peroxidase-conjugated secondary 
antibodies (Promega). Rabbit monoclonal anti-NKD1 
(OriGene) was used diluted 1:4000, mouse monoclonal 
anti-EZH2 (Cell Signaling) was diluted 1:1000, mouse 
monoclonal anti-Myc (Santa Cruz) was diluted 1:1000, 
mouse monoclonal H3 (Abcam) was diluted 1:1000, rabbit 
polyclonal H3K27me3 (Millipore) was diluted 1:10000. 
Rabbit polyclonal anti-β-actin (Sigma) diluted 1:5000 was 
used to reveal β-actin as a loading control.
Histone protein extraction
Cells were harvested and washed twice with ice-
cold PBS. Cells were resuspended in Triton Extraction 
Buffer (TEB: PBS containing 0.5% Triton X 100, 
protease inhibitors) at a cell density of 107 cells per ml 
and incubated on ice for 10 minutes with gentle shaking. 
After centrifuging at 3000 rpm for 10 minutes at 4° C, the 
supernatant was removed and discarded. The pellet was 
resuspended in 25 µl 0.5N HCl and incubated on ice for 
30 minutes. 4 volumes of pre-chilled acetone was added 
to the sample, and histones were let precipitate at –20° C 
overnight. After centrifuging at 13000 rpm for 20 minutes 
at 4° C, the supernatant was removed and the pellet air-
dried and resuspended in distilled water. Protein content 
was determined using the Bradford assay.
Chromatin immunoprecipitation (ChIP) analysis
After cross-linking with 1% formaldehyde, cultured 
cells 48 h post transfection were scraped off in ice-cold 
phosphate-buffered saline plus protease and phosphatase 
inhibitors, centrifuged at 2000 rpm for 5 minutes at 4° C 
and pellets resuspended in L1 Buffer (50 mM TrisHCl 
pH 8.0, 2 mM EDTA pH 8.0, 0.1% NP-40, 10%, glycerol 
plus protease and phosphatase inhibitors) for 15 minutes 
at 4° C in rotation. The lysates were homogenized by 
15 douncer strokes and then centrifuged at 5000 rpm 
for 15 minutes at 4° C, to separate the cytoplasmic from 
the nuclear fraction. The pellets, containing nuclei, were 
resuspended in L2 buffer (50 mM TrisHCl pH 8.0, 5 mM 
EDTA pH 8.0, 1% SDS plus protease and phosphatase 
inhibitors) and incubated for 20 minutes at 4° C in rotation. 
The chromatin was sonicated on ice with 10 pulses for 
10 seconds at 70% settings to obtain chromatin 
fragments of an average length of 300 to 500 base-pairs. 
Successively, chromatin was centrifuged at 10.000 rpm 
for 10 minutes, and supernatants were collected. For each 
sample, two 130 μg aliquots (one for specific antibody 
and one for the species-specific corresponding IgG) 
were diluted 1:10 in Dilution Buffer (50 mM TrisHCl 
pH 8.0, 200 mM NaCl, 5 mM EDTA, 0.5% NP-40) plus 
protease inhibitors, and precleared with 40 μl of Protein 
A Sepharose (Sigma Aldrich) (previously blocked with 
sonicated salmon sperm DNA 200 μg/ml in 3% Bovine 
Serum Albumin) for 3 h at 4° C in rotation. Pre-cleared 
chromatin was centrifuged at 13000 rpm for 5 minutes 
and the supernatant was incubated over night at 4° C 
in rotation with 5 μg of mouse monoclonal α-EZH2 or 
the negative control mouse IgG (ChIPAb+EZH2, clone 
AC22, Millipore), to proceed with immunoprecipitation. 
Immunoprecipitated complexes were collected by 
incubation with 50 μl of Protein A Sepharose for 3 hours 
at 4° C in rotation. The samples were centrifuged at 3000 
rpm for 5 minutes at 4° C and, before washing, 300 μl 
of the supernatant of the IgG sample were collected and 
stored as the Input sample. 
Then the beads were washed in the following buffers 
with protease and phosphatase inhibitors: 
- Low salt (20 mM TrisHCl pH 8.0, 150 mM NaCl, 
2 mM EDTA, 0.1% SDS, 1% TritonX-100) 
- High salt Buffer (20 mM TrisHCl pH 8.0, 500 mM 
NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100) 
Table 2: List of primers used in RT-qPCR analysis
Target gene Forward primer Reverse primer
H19 5′CTGGGCAACGGAGGTGTA3′ 5′CTGGGAGGGTGTCTGCTTC3′
beta-ACTIN 5′ACCGAGCGCGGCTACAG3′ 5′CTTAATGTCACGCACGATTTC3′
Table 3: List of primers used in ChIP analysis of the DNA
Target gene Forward primer Reverse primer
MYT1 5′ACAAAGGCAGATACCCAACG3′ 5′GCAGTTTCAAAAAGCCATCC3′
PPP2R2B 5′CTGGGCAGCAAGCGACTAG3′ 5′TAGACGTGGCCCTTAGCTGAGT3′
MYOD1 5′CCGCCTGAGCAAAGTAAATGA3′ 5′GGCAACCGCTGGTTTGG3′
NKD1 5′AGATCCCAGAGACTGGCTGATAAC3′ 5′CGCACTCCTCTAGTTTCTTATTTGG3′
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- LiCl wash Buffer (10 mM TrisHCl pH 8.0, 0.25M 
LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA) 
- TE wash Buffer (10 mM TrisHCl pH 8.0, 1 mM 
EDTA pH 8.0) After that, immune-complexes were eluted 
twice from Protein A Sepharose with 150 μl of Elution 
buffer (1% SDS and 100 mM NaHCO3) for 15 minutes 
with shaking at RT. 
Then the samples were incubated with 10 μg of 
RNase for 10 minutes at RT and after that, cross-linking 
was reversed by incubating samples at 67° C over-night 
with gentle shaking. Each sample was supplemented with 
6 μl of 1M Tris-HCl pH 6.5 to neutralize NaHCO3, and 
then 12 μl of proteinase K 20 mg/ml was added and the 
reaction conducted for 2 hours at 56° C. Finally, DNA was 
extracted with phenol-chloroform and chloroform and then 
precipitated in 1 volume of 100% isopropanol. The pellet 
was washed with cold 70% ethanol and resuspended in 
50 μl of H20 and chromatin concentration was determined. 
Equal amounts of immunoprecipitated DNA and relative 
controls were used for qPCR analysis. qPCR analysis of 
immunoprecipitated samples (IP) and negative control 
(IgG) were normalized to total chromatin input and 
expressed as (2( –ΔCt)) × 100 (% Input).
Primers employed for ChIP are reported in Table 3.
Chromatin immunoprecipitation of H3K27me3
H3K27me3 ChIP analysis was performed by 
using 5 μg of mouse monoclonal H3K27me3 antibody 
(07-449; Millipore Corp.) or mouse IgG (Millipore 
Corp.) with Dynabeads Magnetic (Invitrogen). After 
washes, samples were eluted with the elution buffer (TE 
1×, sodium dodecyl sulfate 0.5%), treated with RNase A 
and with proteinase K. DNA was extracted with phenol-
chloroform. Equal amounts of immunoprecipitated DNA 
and relative controls were used for qPCR analysis. qPCR 
analysis of immunoprecipitated samples (IP) and negative 
control (IgG) were normalized to total chromatin input and 
expressed as (2( −ΔCt)) × 100 (% Input).
RNA in situ hybridization
Cells were grown on 24 × 24 mm coverglasses in 
a 6-well cell culture plate. Stellaris® RNA FISH Probes 
(Biosearch® Technologies) were used for the detection of RNA 
according to the manufacturer’s protocol for adherent cells. 
The probes were incubated in the dark at 37° C for 4 hours. 
Coverglasses were mounted by placing a drop of ProLong® 
Diamond Antifade Mountant with DAPI (Life Technologies). 
The probes used were: Human H19 with Quasar® 570 Dye or 
Human GAPDH with Quasar® 570 Dye. The microscope used 
to capture images was Leica DMI 6000B.
Migration and invasion assays
A172 and LN229 cells were plated in DMEM 
culture medium without serum on BD BioCoat Control 
Cell Culture Insert Systems or on BD BioCoat Matrigel 
Invasion Chamber (BD Bioscience) at 25 × 103 cells/
chamber for migration or invasion assays, respectively. 
The chemoattractant (DMEM supplemented with 10% 
FBS) was added to the bottom wells of the plate.
The cells were incubated at 37° C, 5% CO2, for 6 h 
for migration and 24 h for invasion. After incubation, the 
non-migrated/invaded cells were removed from the upper 
surface of the membrane by scrubbing with a cotton tipped 
swab, while the cells migrated/invaded adhering to the 
bottom surface of the membrane were fixed with 100% 
MetOH and stained with 0.1% crystal violet, 3% EtOH. The 
number of migrated or invaded cells was evaluated in three 
different fields of three different wells for each condition.
MTS cell viability analysis
A172 and LN229 cells were trypsinized, harvested 
and seeded onto 96-well flat-bottomed plates at a density 
of 2,000 cells/well, then incubated at 37° C for 24 h in 
DMEM supplemented with 10% FBS. Subsequently, 
the cells were subjected to CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega), according 
to the manufacturer’s protocol. The absorbance at 490 
nm was evaluated using a BP800 Microplate Absorbance 
Reader (Headquarters BiohitOyj).
Statistical analysis
Paired t-test and GraphPad Prism version 5.00 
(GraphPad software, San Diego, CA, USA; http://www.
graphpad.com) were used. A p-value (P) < 0.05 was 
considered statistically significant. Data were obtained 
from independent experiments (n = 3) expressed as 
means ± SD. Factor analysis with varimax rotation was 
performed in Statistica (Statsoft) v. 10.
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